Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Fuchs heterochromic iridocyclitis (FHI) is an ocular disease of unknown etiology occurring in a very small percentage (0.5-6.2%) of uvietis cases, characterized by diffuse iris heterochromia or atrophy, keratic precipitates in the absence of synechiae, and in some cases evolving to glaucoma and vitreous opacities.
Features include very common findings: Iris atrophy, Corneal keratic precipitates, Anterior chamber inflammatory cells, and Vitreous floaters; and common findings: Cataract, Blurred vision, Heterochromia iridis, and Koeppe nodules and others. 23 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 8 | Corneal keratic precipitates, Cataract, Blurred vision |
Biomarker and diagnostic research for Fuchs heterochromic iridocyclitis has been reported in the published literature.
Phenotype severity distribution: 4 very common features, 5 common features.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
No clinical trials have been registered for Fuchs heterochromic iridocyclitis.
9 publications have been identified in PubMed for Fuchs heterochromic iridocyclitis. Research spans Case Report / Case Series (33%), Diagnostic / Biomarker (22%), and Review / Meta-Analysis (22%).
Sevim MS (2026). [PMID: 41794659](https://pubmed.ncbi.nlm.nih.gov/41794659/). *BMC ophthalmology*. [Clinical Trial Publication]
Moshirfar M (2026). [PMID: 32644574](https://pubmed.ncbi.nlm.nih.gov/32644574/). *Unknown Journal*. [Review / Meta-Analysis]
Belletti M (2026). [PMID: 41417717](https://pubmed.ncbi.nlm.nih.gov/41417717/). *Ocul Immunol Inflamm*. [Review / Meta-Analysis]
Alghamdi AH (2025). [PMID: 41332050](https://pubmed.ncbi.nlm.nih.gov/41332050/). *Int J Surg Case Rep*. [Case Report / Case Series]
Kianersi F (2025). [PMID: 41367835](https://pubmed.ncbi.nlm.nih.gov/41367835/). *Saudi J Ophthalmol*. [Diagnostic / Biomarker]
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 3:40 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Fuchs heterochromic iridocyclitis
Skin |
2 |
Koeppe nodules, Bussaca nodules |
Muscles | 1 | Iris atrophy |
Heart and blood vessels | 1 | Ocular hypertension |
Kianersi F (2024). [PMID: 38997641](https://pubmed.ncbi.nlm.nih.gov/38997641/). *BMC Ophthalmol*. [Diagnostic / Biomarker]
Kianersi F (2024). [PMID: 38616214](https://pubmed.ncbi.nlm.nih.gov/38616214/). *Scientific reports*. [Epidemiology / Natural History]
Babu K (2024). [PMID: 38153980](https://pubmed.ncbi.nlm.nih.gov/38153980/). *Indian J Ophthalmol*. [Case Report / Case Series]